Encyclopedia of AIDS

Living Edition
| Editors: Thomas J. Hope, Douglas Richman, Mario Stevenson

The Cellular Immune Response to HIV-2 Infection

  • Sophie M. Andrews
  • Glenn Wong
  • Sarah L. Rowland-Jones
Living reference work entry
DOI: https://doi.org/10.1007/978-1-4614-9610-6_38-1

Definition

T-cells play a central role in both the control and pathogenesis of HIV infection. While T-cell responses against HIV-1 infection have been studied in great detail, much less is known about T-cells in the context of HIV-2. This entry summarizes current understanding of the quantitative and qualitative characteristics of HIV-2-specific CD8+ and CD4+ T-cell responses, highlighting key areas in which they may differ from responses against HIV-1, and the clinical implications of such disparities.

Introduction

Although HIV-1 and HIV-2 share substantial similarity in terms of genome and life cycle, there are clear epidemiological and prognostic distinctions between them. An important distinguishing feature of infection is the distribution and time to clinical progression (Marlink et al. 1994). In contrast to HIV-1 infection, where the overwhelming majority of treatment-naïve patients develop AIDS within approximately a decade, the outcome of HIV-2 infection follows an unusual...

Keywords

Dual Infection Undetectable Plasma Viral Load Alternative Protective Mechanism Soluble Antiviral Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Ahmed RKS, Nilsson C, Wang YF, Lehner T, Biberfeld G, Thorstensson R. Beta-chemokine production in macaques vaccinated with live attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. J Gen Virol. 1999;80:1569–74.CrossRefPubMedGoogle Scholar
  2. Ahmed RKS, Mäkitalo B, Karlén K, Nilsson C, Biberfeld G, Thorstensson R. Spontaneous production of RANTES and antigen-specific IFN-γ production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge. Clin Exp Immunol. 2002;129:11–8.PubMedCentralCrossRefPubMedGoogle Scholar
  3. Ahmed RK, Norrgren H, da Silva Z, Blaxhult A, Fredriksson EL, Biberfeld G, Andersson S, Thorstensson R. Antigen-specific beta-chemokine production and CD8 T-cell noncytotoxic antiviral activity in HIV-2-infected individuals. Scand J Immunol. 2005;61:63–71.CrossRefPubMedGoogle Scholar
  4. Alatrakchi N, Damond F, Matheron S, Beretta-Tempelhoff S, Campa P, Carcelain G, Brun-Vezinet F, Autran B. Proliferative, IFN gamma and IL-2-producing T-cell responses to HIV-2 in untreated HIV-2 infection. AIDS. 2006;20:29–34.CrossRefPubMedGoogle Scholar
  5. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science. 1996;272:1955–8.CrossRefPubMedGoogle Scholar
  6. Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, Christopherson C, Biberfeld G, Albert J. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med. 2000;160:3286–93.CrossRefPubMedGoogle Scholar
  7. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8:379–85.CrossRefPubMedGoogle Scholar
  8. Ariyoshi K, Cham F, Berry N, Jaffar S, Sabally S, Corrah T, Whittle H. HIV-2-specific cytotoxic T-lymphocyte activity is inversely related to proviral load. AIDS. 1995;9:555–9.CrossRefPubMedGoogle Scholar
  9. Ariyoshi K, Jaffar S, Alabi AS, Berry N, Schim van der Loeff M, Sabally S, N’Gom PT, Corrah T, Tedder R, Whittle H. Plasma RNA viral load predicts the rate of CD4 T cell decline and death in HIV-2-infected patients in West Africa. AIDS. 2000;14:339–44.CrossRefPubMedGoogle Scholar
  10. Berry N, Jaffar S, Van der Loeff MS, Ariyoshi K, Harding E, N’Gom PT, Dias F, Wilkins A, Ricard D, Aaby P, et al. Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagers. AIDS Res Hum Retroviruses. 2002;18:1167–73.CrossRefPubMedGoogle Scholar
  11. Bertoletti A, Cham F, McAdam S, Rostron T, Rowland-Jones S, Sabally S, Corrah T, Ariyoshi K, Whittle H. Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades. J Virol. 1998;72:2439–48.PubMedCentralPubMedGoogle Scholar
  12. Blackbourn DJ, Locher CP, Ramachandran B, Barnett SW, Murthy KK, Carey KD, Brasky KM, Levy JA. CD8+ cells from HIV-2-infected baboons control HIV replication. AIDS. 1997;11:737–46.CrossRefPubMedGoogle Scholar
  13. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–10.PubMedCentralPubMedGoogle Scholar
  14. Brun-Vezinet F, Katlama C, Roulot D, Lenoble L, Alizon M, Madjar JJ, Rey MA, Girard PM, Yeni P, Clavel F, et al. Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Lancet. 1987;329:128–32.CrossRefGoogle Scholar
  15. Clavel F, Mansinho K, Chamaret S, Guetard D, Favier V, Nina J, Santos-Ferreira MO, Champalimaud JL, Montagnier L. Human immunodeficiency virus type 2 infection associated with AIDS in West Africa. N Engl J Med. 1987;316:1180–5.CrossRefPubMedGoogle Scholar
  16. Cocchi F, DeVico AL, Garzino-Demo A, Cara A, Gallo RC, Lusso P. The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med. 1996;2:1244–7.CrossRefPubMedGoogle Scholar
  17. Cocchi F, DeVico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, Garzino-Demo A, Colombini-Hatch S, Margolis D, Gallo RC. Higher macrophage inflammatory protein (MIP)-1α and MIP-1β levels from CD8(+) T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci U S A. 2000;97:13812–7.PubMedCentralCrossRefPubMedGoogle Scholar
  18. Cordeil S, Nguyen XN, Berger G, Durand S, Ainouze M, Cimarelli A. Evidence for a different susceptibility of primate lentiviruses to type I interferons. J Virol. 2013;87:2587–96.PubMedCentralCrossRefPubMedGoogle Scholar
  19. de Silva T, Leligdowicz A, Rowland-Jones S. Effect of HIV-2 infection on HIV-1 disease progression – author reply 2–3. N Engl J Med. 2012;367:1961–2.CrossRefPubMedGoogle Scholar
  20. de Silva TI, Peng Y, Leligdowicz A, Zaidi I, Li L, Griffin H, Blais ME, Vincent T, Saraiva M, Yindom LM, et al. Correlates of T-cell-mediated viral control and phenotype of CD8(+) T cells in HIV-2, a naturally contained human retroviral infection. Blood. 2013;121:4330–9.CrossRefPubMedGoogle Scholar
  21. Dittmer U, Luke W, Stahl-Hennig C, Coulibaly C, Petry H, Bodemer W, Hunsmann G, Voss G. Early helper T-cell dysfunction in simian immunodeficiency virus but not in human immunodeficiency virus type-2-infected macaques. J Med Primatol. 1994;23:298–303.CrossRefPubMedGoogle Scholar
  22. Duvall MG, Jaye A, Dong T, Brenchley JM, Alabi AS, Jeffries DJ, van der Sande M, Togun TO, McConkey SJ, Douek DC, et al. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol. 2006;176:6973–81.CrossRefPubMedGoogle Scholar
  23. Duvall MG, Lore K, Blaak H, Ambrozak DA, Adams WC, Santos K, Geldmacher C, Mascola JR, McMichael AJ, Jaye A, et al. Dendritic cells are less susceptible to human immunodeficiency virus type 2 (HIV-2) infection than to HIV-1 infection. J Virol. 2007;81:13486–98.PubMedCentralCrossRefPubMedGoogle Scholar
  24. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, Roederer M, Rowland-Jones SL, Koup RA. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol. 2008;38:350–63.PubMedCentralCrossRefPubMedGoogle Scholar
  25. Esbjornsson J, Mansson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, da Silva ZJ, Jansson M, Fenyo EM, Norrgren H, et al. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N Engl J Med. 2012;367:224–32.CrossRefPubMedGoogle Scholar
  26. Gillespie GM, Pinheiro S, Sayeid-Al-Jamee M, Alabi A, Kaye S, Sabally S, Sarge-Njie R, Njai H, Joof K, Jaye A, et al. CD8+ T cell responses to human immunodeficiency viruses type 2 (HIV-2) and type 1 (HIV-1) gag proteins are distinguishable by magnitude and breadth but not cellular phenotype. Eur J Immunol. 2005;35:1445–53.CrossRefPubMedGoogle Scholar
  27. Gotch FM, Nixon DF, Alp N, McMichael AJ, Boryslewicz LK. High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropositive individuals. Int Immunol. 1990;2:707–12.CrossRefPubMedGoogle Scholar
  28. Gotch F, McAdam SN, Allsopp CE, Gallimore A, Elvin J, Kieny MP, Hill AV, McMichael AJ, Whittle HC. Cytotoxic T cells in HIV2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. J Immunol. 1993;151:3361–9.PubMedGoogle Scholar
  29. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS. 2001;15:2319–21.CrossRefPubMedGoogle Scholar
  30. Hamel DJ, Sankale JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup S, Kanki PJ. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses. 2007;23:1189–96.CrossRefPubMedGoogle Scholar
  31. Hansmann A, van der Loeff MFS, Kaye S, Awasana AA, Sarge-Njie R, O’Donovan D, Ariyoshi K, Alabi A, Milligan P, Whittle HC. Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in The Gambia. J Acquir Immune Defic Syndr. 2005;38:335–41.PubMedGoogle Scholar
  32. Jaye A, Sarge-Njie R, van der Loeff MS, Todd J, Alabi A, Sabally S, Corrah T, Whittle H. No differences in cellular immune responses between asymptomatic HIV type 1– and type 2–infected Gambian patients. J Infect Dis. 2004;189:498–505.CrossRefPubMedGoogle Scholar
  33. Jennes W, Camara M, Dièye T, Mboup S, Kestens L. Higher homologous and lower cross-reactive gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection. J Virol. 2008;82:8619–28.PubMedCentralCrossRefPubMedGoogle Scholar
  34. Koblavi-Deme S, Kestens L, Hanson D, Otten RA, Borget MY, Bile C, Wiktor SZ, Roels TH, Chorba T, Nkengasong JN. Differences in HIV-2 plasma viral load and immune activation in HIV-1 and HIV-2 dually infected persons and those infected with HIV-2 only in Abidjan, Cote D’Ivoire. AIDS. 2004;18:413–9.CrossRefPubMedGoogle Scholar
  35. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650–5.PubMedCentralPubMedGoogle Scholar
  36. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474:654–U132.PubMedCentralCrossRefPubMedGoogle Scholar
  37. Leligdowicz A, Yindom LM, Onyango C, Sarge-Njie R, Alabi A, Cotten M, Vincent T, da Costa C, Aaby P, Jaye A, et al. Robust gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest. 2007;117:3067–74.PubMedCentralCrossRefPubMedGoogle Scholar
  38. Leligdowicz A, Onyango C, Yindom LM, Peng Y, Cotten M, Jaye A, McMichael A, Whittle H, Dong T, Rowland-Jones S. Highly avid, oligoclonal, early-differentiated antigen-specific CD8+ T cells in chronic HIV-2 infection. Eur J Immunol. 2010;40:1963–72.CrossRefPubMedGoogle Scholar
  39. Lopes AR, Jaye A, Dorrell L, Sabally S, Alabi A, Jones NA, Flower DR, De Groot A, Newton P, Lascar RM, et al. Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection. J Immunol. 2003;171:307–16.CrossRefPubMedGoogle Scholar
  40. Manel N, Hogstad B, Wang Y, Levy DE, Unutmaz D, Littman DR. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature. 2010;467:214–7.PubMedCentralCrossRefPubMedGoogle Scholar
  41. Mansson F, Biague A, da Silva ZJ, Dias F, Nilsson LA, Andersson S, Fenyo EM, Norrgren H. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS. 2009;23:1575–82.CrossRefPubMedGoogle Scholar
  42. Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh C, Dia M, Gueye E, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science. 1994;265:1587–90.CrossRefPubMedGoogle Scholar
  43. Martinez-Steele E, Awasana AA, Corrah T, Sabally S, van der Sande M, Jaye A, Togun T, Sarge-Njie R, McConkey SJ, Whittle H, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS. 2007;21:317–24.CrossRefPubMedGoogle Scholar
  44. Mothe BR, Horton H, Carter DK, Allen TM, Liebl ME, Skinner P, Vogel TU, Fuenger S, Vielhuber K, Rehrauer W, et al. Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J Virol. 2002;76:875–84.PubMedCentralCrossRefPubMedGoogle Scholar
  45. Mulder DW, Nunn AJ, Kamali A, Nakiyingi J, Wagner HU, Kengeyakayondo JF. 2-year HIV-1-associated mortality in a Ugandan rural-population. Lancet. 1994;343:1021–3.CrossRefPubMedGoogle Scholar
  46. Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, Miedema F, Kootstra N, Schuitemaker H. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol. 2007;179:3133–43.CrossRefPubMedGoogle Scholar
  47. Norrgren H, Andersson S, Biague AJ, da Silva ZJ, Dias F, Naucler A, Biberfeld G. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, west Africa: no protection of HIV-2 against HIV-1 infection. AIDS. 1999;13:701–7.CrossRefPubMedGoogle Scholar
  48. Pantaleo G, Demarest JF, Schacker T, Vaccarezza M, Cohen OJ, Daucher M, Graziosi C, Schnittman SS, Quinn TC, Shaw GM, et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A. 1997;94:254–8.PubMedCentralCrossRefPubMedGoogle Scholar
  49. Poulsen AG, Aaby P, Larsen O, Jensen H, Nauclér A, Lisse IM, Christiansen CB, Dias F, Melbye M. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet. 1997;349:911–4.Google Scholar
  50. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, Lindqvist M, Pereyra F, Walker BD, Heckerman D, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J Virol. 2012;86(1):277–83.PubMedCentralCrossRefPubMedGoogle Scholar
  51. Raugi DN, Gottlieb GS, Sow PS, Toure M, Sall F, Gaye A, N’Doye I, Kiviat NB, Hawes SE. HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4(+) cell counts. AIDS. 2013;27:2441–50.PubMedCentralCrossRefPubMedGoogle Scholar
  52. Rowland-Jones SL, Whittle HC. Out of Africa: what can we learn from HIV-2 about protective immunity to HIV-1? Nat Immunol. 2007;8:329–31.CrossRefPubMedGoogle Scholar
  53. Sarr AD, Lu Y, Sankale JL, Eisen G, Popper S, Mboup S, Kanki PJ, Cao H. Robust HIV type 2 cellular immune response measured by a modified anthrax toxin-based enzyme-linked immunospot assay. AIDS Res Hum Retroviruses. 2001;17:1257–64.CrossRefPubMedGoogle Scholar
  54. Thiebaut R, Matheron S, Taieb A, Brun-Vezinet F, Chene G, Autran B. Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort. AIDS. 2011;25:865–7.CrossRefPubMedGoogle Scholar
  55. Travers K, Mboup S, Marlink R, Gueye-Nidaye A, Siby T, Thior I, Traore I, Dieng-Sarr A, Sankale JL, Mullins C, et al. Natural protection against HIV-1 infection provided by HIV-2. Science. 1995;268:1612–5.CrossRefPubMedGoogle Scholar
  56. van der Loeff MFS, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, van Tienen C, Leligdowicz A, Sarge-Njie R, da Silva Z, et al. Undetectable plasma viral load predicts normal survival in HIV-2-infected people in a West African village. Retrovirology. 2010;7:1–10.CrossRefGoogle Scholar
  57. van Tienen C, Schim van der Loeff M, Peterson I, Cotten M, Andersson S, Holmgren B, Vincent T, de Silva T, Rowland-Jones S, Aaby P, et al. HTLV-1 and HIV-2 infection are associated with increased mortality in a rural West African community. PLoS One. 2011;6, e29026.PubMedCentralCrossRefPubMedGoogle Scholar
  58. Voss G, Nick S, Otteken A, Luke W, Stahl-Hennig C, Hunsmann G. Virus-specific cytotoxic T-lymphocytes in HIV-2-infected cynomolgus macaques. AIDS. 1992;6:1077–83.CrossRefPubMedGoogle Scholar
  59. Ylinen LM, Keckesova Z, Wilson SJ, Ranasinghe S, Towers GJ. Differential restriction of human immunodeficiency virus type 2 and simian immunodeficiency virus SIVmac by TRIM5alpha alleles. J Virol. 2005;79:11580–7.PubMedCentralCrossRefPubMedGoogle Scholar
  60. Zheng NN, Kiviat NB, Sow PS, Hawes SE, Wilson A, Diallo-Agne H, Critchlow CW, Gottlieb GS, Musey L, McElrath MJ. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. J Virol. 2004;78:13934–42.PubMedCentralCrossRefPubMedGoogle Scholar
  61. Zheng NN, McElrath MJ, Sow P-S, Hawes SE, Diallo-Agne H, Stern JE, Li F, Mesher AL, Robinson AD, Gottlieb GS, et al. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol. 2007;81:9061–71.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Sophie M. Andrews
    • 1
  • Glenn Wong
    • 1
  • Sarah L. Rowland-Jones
    • 1
  1. 1.Nuffield Department of MedicineUniversity of OxfordOxfordUK